ATLANTA, GA — March 19, 2002 — Pfizer Inc reported that for the first time, new sub-study data showed that patients who experienced an acute coronary syndrome (ACS) and were treated with Lipitor® (atorvastatin calcium) experienced a greater reduction in C-reactive protein (CRP) than those treated with placebo.
The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) sub-study results were presented today at the 51st Annual Scientific Sessions of the American College of Cardiology (ACC).
C-reactive protein is a marker of inflammation that is believed to be associated with the atherosclerotic process. A reduction in inflammation may be associated with plaque stabilization in patients with ACS (also known as mild heart attack or severe chest pain).
"The MIRACL sub-study suggests that Lipitor is effective in reducing CRP levels in ACS patients," said Scott Kinlay, MBBS, PhD, Cardiovascular Division, Brigham and Women's Hospital, in Boston, Massachusetts, United States.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!